Skip to content
Screener

Bioventus BVS Allowance for Doubtful Accounts Receivable (Current)

Allowance for Doubtful Accounts Receivable (Current) at other companies

Xtant Medical Holdings logo
Xtant Medical HoldingsXTNT
$2.23M+24.5%
Globus Medical logo
Globus MedicalGMED
$44.37M+66.8%
Enovis logo
EnovisENOV
$28.18M0.0%
SI-BONE, Inc. logo
SI-BONE, Inc.SIBN
$1.06M+79.7%
OrthoPediatrics logo
OrthoPediatricsKIDS
$1.68M+19.1%
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$153.2M+3.8%
Gross profit$105.7M+3.5%
Operating income$19.1M+4.1%
Net income$33.4M+348%
EPS (diluted)$0.47+327%

Balance sheet

See full
Cash & equivalents$29.5M-10.5%
Total debt$263.7M-26.9%
Total equity$228.3M+41.6%
Total assets$673.3M-4.7%

Cash flow

See full
Operating cash flow$19.9M-23.4%
CapEx$960.0K+40.6%
Free cash flow$18.9M-25.1%

Valuation

See full
Market cap$1.17B+153%
Enterprise value$1.41B+78.0%
P/E21.6×
P/S+1.2×

Profitability

See full
Gross margin68.7%+1.1pp
Operating margin10%
Net margin9.4%+9.2pp
FCF margin16.2%+10.2pp

Returns & leverage

See full
Return on equity28%+27.5pp
Debt / equity1.2×-1.1×
Current ratio1.7×+0.2×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent.

The source filing: Bioventus’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 7:43 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001665988-26-000042
Line itemJune 27, 2026December 31, 2025
Accounts receivable$141,018$131,206
Less: Allowance for credit losses(2,612)(2,903)
$138,406$128,303

Item 1. Financial Statements (Unaudited)

FAQ

What is Bioventus's allowance for doubtful accounts receivable (current)?
Bioventus (BVS) reported allowance for doubtful accounts receivable (current) of $2.61M in Q2 2026.
How has Bioventus's allowance for doubtful accounts receivable (current) changed year-over-year?
Bioventus's allowance for doubtful accounts receivable (current) decreased by 9.9% year-over-year, from $2.9M to $2.61M.
What is the long-term trend for Bioventus's allowance for doubtful accounts receivable (current)?
Over 5 years (2020 to 2025), Bioventus's allowance for doubtful accounts receivable (current) has grown at a -6.2% compound annual growth rate (CAGR), from $3.99M to $2.9M.
What does allowance for doubtful accounts receivable (current) mean?
This is the valuation allowance for current receivables that are considered uncollectible due to disputes, bankruptcy, or other non-payment issues. It serves as a buffer against potential losses from customer defaults. It is a critical indicator of the health of the company's accounts receivable portfolio.

Ask your AI about Bioventus's allowance for doubtful accounts receivable (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude